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Abstract
Background: Toxic Shock Syndrome is a dangerous disease with clinical features mimicking
bacterial sepsis. The best management of Toxic Shock Syndrome is not determined.
Case presentation: A 28 year-old woman presenting with high fever, tachycardia and widespread
erythroderma is described. She failed to respond to intravenous antibiotics and required ITU
admission. High dose corticosteroids dramatically improved her clinical condition.
Conclusion:  Toxic Shock Syndrome should be considered in the differential diagnosis of
unexplained fever, rash and features resembling septic shock. Corticosteroids should be
considered in the treatment of Toxic Shock Syndrome.
Background
Toxic Shock Syndrome (TSS) is a super-antigen mediated,
potentially fatal disease [1]. Its rarity ensures it is often
considered late in the clinical course of the disease, and
controlled trials on the best management are lacking. A
case of TSS is described; the illness was refractory to intra-
venous antibiotics but successfully treated with intrave-
nous steroids.
Case report
A 28-year-old woman presented to A&E with a short his-
tory of diarrhoea and vomiting associated with high
fevers, sore throat and flushing of her skin. There had
been no recent foreign travel, exposure to toxins or drugs,
nor gynaecological symptoms. There had been no recent
use of tampons. She had not been menstruating while
using 3-monthly intramuscular injections of Depo-
Provera, a long-acting progesterone, as contraception.
Interestingly, 6 years earlier she had been admitted with a
toxic shock-like syndrome to another hospital and
required ITU care. At that time and without serological
confirmation, it was presumed that a staphylococcal or
possibly streptococcal infection had triggered her condi-
tion.
On examination she looked unwell. She was distressed
and flushed with widespread erythema of her skin. Her
temperature was raised at 39.6°C and pulse elevated at
120 beats per minute with regular rhythm. Her blood
pressure was maintained at 110/70 mmHg. Cardiac aus-
cultation was normal, as was the rest of the clinical exam-
ination. A subsequent pelvic examination was normal.
Blood tests showed a white cell count of 9.4 × 109/l with
left shift of neutrophils. The CRP and ESR were raised at
250 ng/ml and 45 mm/hr respectively. Arterial blood
gases demonstrated respiratory alkalosis with pH 7.57,
pO2 13.8 kPa and pCO2 2.2 kPa. A chest radiograph was
normal.
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She received aggressive intravenous fluid resuscitation.
After blood was drawn for culture, intravenous cefurox-
ime and clarithromycin were empirically prescribed for a
presumed bacterial septic illness. However the antibiotics
failed to control either her pyrexia or her tachycardia. Her
rash initially resembled severe sunburn but went on to
exfoliate and then desquamate after two days. Dermatol-
ogy opinion agreed that the skin condition was consistent
with a diagnosis of TSS, and supportive treatment recom-
mended. Her serum albumin dropped to 20 g/l during the
first few days of her admission. Her temperature remained
elevated at 38–39°C. Repeated blood cultures were sterile
while stool cultures were negative for bacterial pathogens.
All throat, skin and high vaginal swabs yielded no growth.
Paired acute and convalescent antistreptolysin 0 titres and
antistaphylolysin 0 titres showed no rise. Rheumatoid fac-
tor, antinuclear and other autoantibodies were negative.
C1 esterase inhibitor and complement levels were normal.
Screens for viruses, toxic metals, cardiolipin antibody, uri-
nary porphyrins and porphobilinogen were all negative.
Five days after admission her fever rose to 40°C and she
became more unwell with delirium. Her pulse rose to140
beats per minute. An echocardiogram was normal. She
was transferred to the ITU for further observation. Since
no bacteria had been cultured after 5 days and since she
had made no response to antibiotics and remained very
unwell, a decision was made to empirically administer
corticosteroids. This decision was based on anecdotal
reports, and a retrospective analysis had suggested possi-
ble benefit from corticosteroid use [2]. She was given
intravenous methylprednisolone 1 g daily for three days.
Administration of this corticosteroid rapidly and dramat-
ically improved her clinical condition with resolution of
her temperature and tachycardia. She was converted to
oral steroids and discharged home with prednisolone 30
mg daily. The dose was subsequently tapered over 6 weeks
at outpatient follow up, and she remains well 2 years later.
Discussion
TSS is an acute, toxin-mediated febrile illness that can rap-
idly lead to multisystem organ failure. Its characteristic
features of high fever, macular erythrodermic rash (lik-
ened to sunburn), myalgia, diarrhoea and other systemic
upset were evident in the case reported here. A plethora of
toxic proteins have been implicated in its pathogenesis,
most notably the Toxic Shock Syndrome Toxin-1 (TSST-1)
[1]. This protein, secreted by S. aureus, has the ability to
cause a remarkable expansion of T lymphocytes display-
ing specific β chain variable regions of the T-cell antigen
receptor: it is this property that earns TSST-1 classification
as a superantigen. Superantigens bypass normal antigen
presentation and stimulate over 20% of the body's T-cells,
inducing the massive release of various cytokines, prostag-
landins and leukotrienes and initiating a dangerous
inflammatory response.
The first reports of TSS emerged in 1978 [3]. A statistical
association between tampon use and the development of
TSS in women, the recognition that asymptomatic vaginal
ulceration occurs in tampon users, and that S aureus colo-
nises the normal vaginal flora of 5% of women, led to the
hypothesis that ulceration of the vaginal mucosa resulting
from tampon use may provide a common point of entry
for the S aureus exotoxin. Since these toxins can enter the
bloodstream from various different portals, not just the
vaginal mucosa, TSS-like presentations have subsequently
been described in women who are not menstruating, and
in men.
TSS can therefore be divided into menstrual and nonmen-
strual subgroups, with around 45% of all cases being non-
menstrual in origin. Three basic features are thought to be
required to develop TSS: i) patient colonisation or infec-
tion with S aureus, ii) production of TSST-1 or similar tox-
ins by the bacterium, and iii) an entry route for the toxins
into the circulatory system. It should be noted that S
aureus bacteraemia has been found to have no focus in up
to one third of cases [4]. Definite TSS requires the pres-
ence of fever, rash, hypotension, multisystem disease, and
desquamation, with the latter occurring 1–2 weeks after
the onset of illness; absence of 1 criterion constitutes
"probable" TSS. Currently, there is no diagnostic test for
TSS. Although it is hypothesised that the disease can only
manifest in those who are unable to generate sufficient
antibody titres to TSST-1, the absence of TSST-1 antibod-
ies does not help in the diagnosis.
In the case we report, convalescent serum samples for
streptococcal and staphylococcal antibodies were negative
and so the underlying cause of her TSS was not identified.
Our patient had experienced TSS six years earlier. While
recurrence of menstrual TSS is not unusual, recurrent non-
menstrual TSS as in this report, is rarer [5]. Failure to erad-
icate  S. aureus colonization has been the proposed
mechanism.
The differential diagnosis of TSS at presentation in A&E is
broad. Bacterial infection with associated septicaemia
should most rapidly come to mind. The most common of
such infections to be considered is acute pyelonephritis;
the most serious is meningococcal septicaemia. Both of
these should be actively excluded.
Initial management of TSS is supportive, and aggressive
fluid resuscitation is essential. High-dose anti-staphyloc-
cocal antibiosis is recommended, and will almost auto-
matically have been given to treat infective conditions in
the differential diagnosis. Flucloxacillin is an appropriatePublish with BioMed Central    and   every 
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antibiotic choice, and it demonstrably inhibits TSST-1
toxin production in vitro when combined with gentamicin
[6] Pooled human immunoglobulin has also been used in
some patients. Corticosteroids have been occasionally
used in TSS, and one retrospective series suggested some
benefit [2]. Although there are no definitive data to sup-
port the use of corticosteroid treatment in TSS, our patient
responded well to this treatment. Administration of meth-
ylprednisone marked the turning point in her clinical
course, presumably by suppressing the inflammatory
response associated with TSS. While the super-toxin medi-
ated inflammatory illness in TSS must be clearly distin-
guished from more frequently seen septic shock illnesses,
it is interesting that steroids may controversially have a
role in some septic shock patients [7].
In summary, TSS should be included in the differential
diagnosis of a patient with a severe toxic illness with asso-
ciated fever and rash, in the emergency department. Cor-
ticosteroids should be considered in the management of
TSS.
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